Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

Lower Manhattan-based Metsera is one of the latest drug startups to throw its hat into the ring with the pharma giants ...

NEW YORK--(BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced the close of a ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Metsera, already a well-funded ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

with a readout expected before the end of the year. Other players include Metsera, a newly emerged weight loss biotech that ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

After a slow week last week, big rounds saw a good rebound with seven startups raising $100 million or more. While food ...

Despite the competitive nature for funding in the crowded weight loss treatment space, Metsera has won $215m to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) orientated portfolio.